QL
EPRX

Quarry LP’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Quarry LP’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324 Buy
+49
New +$338 ﹤0.01% 2240

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Quarry LP's EPRX Position: Q2 2026 in Review

Quarry LP opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 49 shares worth $324. The stake represents ﹤0.01% of the portfolio and ranks #2240 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Quarry LP held 49 shares of Eupraxia Pharmaceuticals worth $324 as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new Quarry LP position in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #2240 holding.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.